Close
Help





JOURNAL

Clinical Medicine Insights: Blood Disorders

Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia

Submit a Paper


Clinical Medicine Insights: Blood Disorders 2011:4 11-19

Published on 28 Jul 2011

DOI: 10.4137/CMBD.S5118


Further metadata provided in PDF



Sign up for Email Alerts and keep in touch with Clinical Medicine Insights: Blood Disorders journal news, updates, events and articles

Abstract

Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT.


Downloads

PDF  (468.75 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Libertas Academica
We were invited to write a review article for Virology: Research and Treatment.  The review process was very quick and smooth and our interactions with Libertas Academica staff was clear, efficient and very personable.  I highly recommend publishing with this group.
Dr Ana Gervassi (Seattle Biomedical Research Institute and the University of Washington Department of Medicine, Seattle, WA, USA)
More Testimonials

Quick Links


New article and journal news notification services